

Technology Advisory Committee Interests Register

Topic: Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

Publication Date: TBC.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Charles Crawley	TAC B Committee Member	Financial Interests	<p>Charles is on an independent data monitoring committee for a clinical trial for raculizimab (Alexion) in transplant associated TMA (an unrelated condition). Raculizumab has a licence for MG but does not have a positive TA. He has been involved in one DMC meeting to date and has not been paid for this although there is an offer of reimbursement.</p> <p>He is looking to see whether Alexion will make a payment to the Haematology department in Cambridge rather than a direct payment to Charles.</p>	13/06/2024	It was agreed that Charles's declaration would not prevent him from participating in discussions on this appraisal.
David McAllister	TAC B Committee Member	Non-Financial Professional & Personal Interests	David works with data provided by sponsors or their competitors accessed via the Vivli trial data sharing platform.	13/06/2024	It was agreed that David's declaration would not prevent him from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
					participating in discussions on this appraisal.
Dr Channa Hewamadduma	Clinical Expert	Financial Interests	<p>Received honoraria for advisory roles and speaking at educational/conferences: UCB, Argenx, Biogen, Roche, Lupin.</p> <p>UCB Pharma</p> <p>01/01/2021-01/01/2022 (sporadic)</p> <p>06/12/2022, Sept/2023</p> <p>Received honoraria for consultancy on scientific or educational advisory boards or speaker honoraria</p>	<p>05/02/2025</p> <p>13/06/2024</p>	It was agreed that Dr Hewamadduma's declaration would not prevent him from providing expert advice to the committee.
Dr Maria Isabel Leite	Clinical Expert	Professional Interests	<p>Oct/2022 to 2023, Dr Leite has served on advisory and educational boards and acted as a speaker at UCB organised and sponsored educational events.</p> <p>These advisory boards have focussed on the management and treatment of myasthenia gravis and UCB treatments under development for the treatment of myasthenia</p>	<p>05/02/2025</p> <p>09/10/2024</p> <p>13/06/2024</p>	It was agreed that Dr Leite's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>gravis (zilucoplan and rozanolixizumab).</p> <p>The contracted parties for the above were UCB and Oxford University.</p> <p>Oct/2022 to 2023, Dr Leite served on advisory board and acted as speaker at an Argenx organised and sponsored educational event.</p> <p>Those activities have focussed on the management of myasthenia gravis, in general, and on medical treatments, including that developed for generalised myasthenia gravis by Argenx (efgartigimod).</p> <p>The contracted parties for the above were Argenx and Oxford University</p> <p>Oct/2022 to 2023, Dr Leite is a member of the steering committee for a clinical trial developed by Horizon for generalised myasthenia gravis (MINT) and acted as chairman in an educational session</p>		

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			organised and sponsored by Horizon. The contracted parties for the above were Horizon and Oxford University		